Related Experiment Video
Updated: Jan 29, 2026

A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
Falko Lange1,2, Konrad Weßlau1, Katrin Porath1
1Oscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
Abstract:
Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary. While clinical guidelines recommend all approved anticonvulsants, so far it is still unclear which of the available drugs is the best therapeutic option for treating glioma-associated seizures, also in view of possible anti-tumorigenic effects. In our study, we employed four patient-derived low-passage cell lines of glioblastoma and three cell lines of brain metastases, and challenged these cultures with four anticonvulsants with different mechanisms of action: levetiracetam, valproic acid, carbamazepine and perampanel. Cell proliferation was determined by bromodeoxyuridine incorporation. To further analyze the effects of perampanel, apoptosis induction was measured by caspase 3/7 activation. Glutamate release was quantified and glucose uptake was determined using 18F-fluorodeoxyglucose. Real-time polymerase chain reaction was employed to assess the expression of genes associated with glutamate release and uptake in brain tumor cells. Of the four anticonvulsants, only perampanel showed systematic inhibitory effects on cell proliferation, whereas all other anticonvulsants failed to inhibit glioma and metastasis cell growth in vitro. Metastasis cells were much more resistant to perampanel than glioblastoma cell lines. Glucose uptake was attenuated in all glioblastoma cells after perampanel exposure, whereas cell death via apoptosis was not induced. Extracellular glutamate levels were found to be significantly higher in glioblastoma cell lines as compared to metastasis cell lines, but could be reduced by perampanel exposure. Incubation with perampanel up-regulated glutamine synthetase expression in glioblastoma cells, whereas treatment with valproic acid and levetiracetam downregulated excitatory amino acid transporter-2 expression. Overall, our data suggest that perampanel acts as an anticonvulsive drug and additionally mediated anti-tumorigenic effects.
Insights
Perampanel effectively inhibited glioblastoma cell proliferation and reduced glucose uptake, unlike other anticonvulsants. This drug shows potential as an anticonvulsive and anti-tumorigenic agent for brain tumors.
Area of Science:
- Neuro-oncology
- Pharmacology
- Cancer Biology
Background:
- Epileptic seizures are common in glioblastoma patients, necessitating anticonvulsive treatment.
- The optimal anticonvulsant for glioma-associated seizures, considering potential anti-tumor effects, remains unclear.
- Existing treatments lack comprehensive evaluation for dual anticonvulsive and anti-tumorigenic efficacy in brain tumors.
Purpose of the Study:
- To evaluate the efficacy of four anticonvulsants (levetiracetam, valproic acid, carbamazepine, perampanel) against glioblastoma and brain metastasis cell lines.
- To investigate the anti-tumorigenic effects of these anticonvulsants, including impacts on cell proliferation, apoptosis, glucose uptake, and glutamate release.
- To assess the differential effects of perampanel on glioblastoma versus metastasis cell lines.
Main Methods:
- Utilized four patient-derived glioblastoma and three brain metastasis cell lines.
- Assessed cell proliferation via bromodeoxyuridine incorporation and apoptosis via caspase 3/7 activation.
- Quantified glutamate release, glucose uptake (using 18F-fluorodeoxyglucose), and gene expression related to glutamate transport.
Main Results:
- Perampanel demonstrated significant inhibition of glioblastoma cell proliferation, while other anticonvulsants did not affect cell growth in vitro.
- Perampanel exposure attenuated glucose uptake in glioblastoma cells and reduced extracellular glutamate levels.
- Perampanel upregulated glutamine synthetase expression in glioblastoma cells; valproic acid and levetiracetam downregulated excitatory amino acid transporter-2.
Conclusions:
- Perampanel exhibits both anticonvulsive and anti-tumorigenic properties in glioblastoma models.
- Metastasis cell lines showed greater resistance to perampanel's effects compared to glioblastoma cells.
- Findings suggest perampanel as a promising therapeutic candidate for managing seizures and potentially treating brain tumors.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...

